Roche Reports Results of Satralizumab in P-III SAkuraSky Study to Treat Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)

 Roche Reports Results of Satralizumab in P-III SAkuraSky Study to Treat Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)

Roche’s cobas Babesia Blood Test Receives the US FDA’s Approval for Donor Screening

Shots:

  • The P-III SAkuraSky study involves assessing of satralizumab (120mg, SC) + baseline immunosuppressant therapy vs PBO + baseline immunosuppressant therapy in ratio (1:1) in 83 patients with NMOSD
  • P-III study results: relapse-free patients @ 48, 96 and 144wks. (89%, 78%, 74% vs 66%, 59%, 49%), Experienced PDR (20% vs 43%); AQP4-IgG seropositive & seronegative subgroup: experienced a PDR (11% vs 43%) & (36% vs 43%)
  • Satralizumab is a mAb targeting IL-6 receptor and has received Orphan Drug Designation in the US, EU, and Japan plus granted BT designation by the US FDA in Dec 2018 for NMOSD

Click here to­ read full press release/ article | Ref: Roche | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post